191 – 200 of 533
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study
(
- Contribution to journal › Article
-
Mark
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
(
- Contribution to journal › Article
- 2018
-
Mark
Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men
(
- Contribution to journal › Article
-
Mark
Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy : Results from the LAParoscopic Prostatectomy Robot Open Trial
(
- Contribution to journal › Article
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial
(
- Contribution to journal › Article
-
Mark
Re : Is Preoperative Assessment and Treatment of Asymptomatic Bacteriuria Necessary for Reducing the Risk of Postoperative Symptomatic Urinary Tract Infection After Urologic Surgical Procedures?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Generalization of prostate cancer classification for multiple sites using deep learning
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Social constraints and psychological well-being after prostate cancer : A follow-up at 12 and 24 months after surgery
(
- Contribution to journal › Article
-
Mark
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
(
- Contribution to journal › Article